Yes Bart, you're right. It just did not sit right that this study is getting all this extensive coverage by the media when OvaDx is so far superior. Fujirebio Diagnostics Inc, which is behind this study effort, really know how to do PR. Wish that Arrayit Diagnostics was this good at PR.
The one thing that more awareness of OvaDx could do is bring is investors to Arrayit.
Market Data 
Markets 
AI
